Unnamed: 0,title,date,stock,sentiment
90459.0,"The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates",2020-06-09 07:46:00-04:00,ARDX,negative
90460.0,Ardelyx Appoints Justin Renz as Chief Financial Officer,2020-06-08 16:03:00-04:00,ARDX,neutral
90461.0,Ardelyx Appoints Susan Rodriguez As Chief Commercial Officer,2020-05-18 16:03:00-04:00,ARDX,neutral
90462.0,"Ardelyx Q1 EPS $(0.250) Up From $(0.420) YoY, Sales $1.213M",2020-05-07 16:23:00-04:00,ARDX,neutral
90463.0,"Ardelyx Q4 EPS $(0.27) Up From $(0.45) YoY, Sales $2.25M Up From $85K YoY",2020-03-06 16:03:00-05:00,ARDX,neutral
90464.0,"Ardelyx shares are trading lower with the overall market amid continued coronavirus concerns, which have negatively impacted demand outlook.",2020-02-21 11:57:00-05:00,ARDX,negative
90465.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-20 10:26:00-05:00,ARDX,neutral
90466.0,80 Biggest Movers From Yesterday,2020-02-19 04:28:00-05:00,ARDX,neutral
90467.0,35 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-02-18 08:25:00-05:00,ARDX,neutral
90468.0,"Benzinga's Top Upgrades, Downgrades For February 12, 2020",2020-02-12 09:40:00-05:00,ARDX,positive
90469.0,"Citigroup Initiates Coverage On Ardelyx with Buy Rating, Announces $13 Price Target",2020-02-12 06:09:00-05:00,ARDX,neutral
90470.0,"Benzinga's Top Upgrades, Downgrades For February 10, 2020",2020-02-10 10:20:00-05:00,ARDX,positive
90471.0,Cowen & Co. Initiates Coverage On Ardelyx with Outperform Rating,2020-02-10 06:27:00-05:00,ARDX,neutral
90472.0,"Ardelyx Says it Has $247.5M in Cash and Cash Equivalents, Enough to Fund the Company Thorugh 2022",2020-01-13 06:58:00-05:00,ARDX,neutral
90473.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,ARDX,neutral
90474.0,"The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering",2019-12-20 08:12:00-05:00,ARDX,positive
90475.0,17 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-05 07:55:00-05:00,ARDX,neutral
90476.0,40 Stocks Moving in Thursday's Pre-Market Session,2019-12-05 07:30:00-05:00,ARDX,neutral
90477.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,ARDX,positive
90478.0,72 Biggest Movers From Yesterday,2019-12-05 05:10:00-05:00,ARDX,neutral
90479.0,Ardelyx Reports $80M Common Stock Offering,2019-12-04 16:58:00-05:00,ARDX,neutral
90480.0,"Shares of small-cap biotech company Ardelyx are trading lower, reversing from Tuesday strength in a potential sell off. Shares surged Tuesday following results from the company's Phase 3 PHREEDOM trial in chronic kidney disease patients.",2019-12-04 11:57:00-05:00,ARDX,positive
90481.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,ARDX,negative
90482.0,63 Biggest Movers From Yesterday,2019-12-04 05:15:00-05:00,ARDX,neutral
90483.0,Ardelyx shares are trading higher after the company announces positive topline results from its Phase 3 of PHREEDOM. Jefferies also maintained its Buy rating and raised its price target from $6 to $11 per share.,2019-12-03 13:56:00-05:00,ARDX,positive
90484.0,"UPDATE: Jefferies On Ardelyx Notes 'The co is targeting an NDA submission in mid '20 and approval in mid '21. We raise our PT to $11 on a lower risk discount on topline tenapanor revenue, and a lower WACC in the DCF'",2019-12-03 13:51:00-05:00,ARDX,negative
90485.0,"UPDATE: Jefferies Maintains Buy On Ardelyx, Raises Tgt To $11 After Co's 'positive topline data from the pivotal PHREEDOM study, where tenapanor treated pts saw mean decreases in serum phosphorus and an AE profile consistent with the initial ph 3 study'",2019-12-03 13:51:00-05:00,ARDX,positive
90486.0,Jefferies Raises Ardelyx Price Target From $6 To $11 Following PHREEDOM Study Data,2019-12-03 13:41:00-05:00,ARDX,neutral
90487.0,"Hearing BTIG Out Positive On Ardelyx, Reiterates $15 Price Target; Unconfirmed",2019-12-03 13:38:00-05:00,ARDX,positive
90488.0,"The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial",2019-12-03 07:59:00-05:00,ARDX,neutral
90489.0,Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis,2019-12-03 07:28:00-05:00,ARDX,positive
90490.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,ARDX,negative
90491.0,60 Biggest Movers From Yesterday,2019-11-27 05:03:00-05:00,ARDX,neutral
90492.0,"Ardelyx shares are trading higher after Kyowa Kirin made a $20 million equity investment in the company at $6.96 for 2,873,563 shares.",2019-11-26 08:53:00-05:00,ARDX,positive
90493.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,ARDX,positive
90494.0,Ardelyx Reports Expansion Of Partnership With Kyowa Kirin,2019-11-25 18:10:00-05:00,ARDX,neutral
90495.0,"Kyowa Kirin Has Made a $20 Million Equity Investment in Ardelyx at $6.96 for 2,873,563 Shares",2019-11-25 18:04:00-05:00,ARDX,positive
90496.0,"Ardelyx, Kyowa Kirin Establish Two-Year Research Collaboration",2019-11-25 18:03:00-05:00,ARDX,neutral
90497.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,ARDX,positive
90498.0,77 Biggest Movers From Yesterday,2019-11-20 04:57:00-05:00,ARDX,neutral
90499.0,Shares of microcap biotech company Ardelyx are trading higher. Not currently seeing any company-specific news.,2019-11-19 14:55:00-05:00,ARDX,positive
90500.0,Ardelyx shares are trading higher after the company reported Q3 EPS results.,2019-11-08 11:39:00-05:00,ARDX,positive
90501.0,"Ardelyx Q3 EPS $(0.37), Inline",2019-11-06 16:52:00-05:00,ARDX,neutral
90502.0,48 Biggest Movers From Yesterday,2019-10-18 06:55:00-04:00,ARDX,neutral
90503.0,32 Stocks Moving In Thursday's Mid-Day Session,2019-10-17 11:52:00-04:00,ARDX,neutral
90504.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2019-09-30 16:32:00-04:00,ARDX,neutral
90505.0,"SVB Leerink Maintains Outperform on Ardelyx, Raises Price Target to $9",2019-09-24 08:24:00-04:00,ARDX,neutral
90506.0,56 Biggest Movers From Friday,2019-09-16 05:29:00-04:00,ARDX,neutral
90507.0,"The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck",2019-09-15 11:18:00-04:00,ARDX,positive
90508.0,Mid-Afternoon Market Update: Park City Falls Following Q4 Results; MER Telemanagement Solutions Shares Climb,2019-09-13 15:22:00-04:00,ARDX,positive
90509.0,35 Stocks Moving In Friday's Mid-Day Session,2019-09-13 12:56:00-04:00,ARDX,neutral
90510.0,Mid-Day Market Update: Vince Holding Surges After Q2 Results; Ritter Pharmaceuticals Shares Slide,2019-09-13 12:54:00-04:00,ARDX,positive
90511.0,"A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019",2019-09-13 12:29:00-04:00,ARDX,neutral
90512.0,Mid-Morning Market Update: Markets Mostly Higher; Fibrocell Receives Cash Bid From Castle Creek Pharma,2019-09-13 10:27:00-04:00,ARDX,neutral
90513.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Friday, September 13,  2019",2019-09-13 09:02:00-04:00,ARDX,positive
90514.0,24 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-13 08:44:00-04:00,ARDX,neutral
90515.0,24 Stocks Moving in Friday's Pre-Market Session,2019-09-13 07:54:00-04:00,ARDX,neutral
90516.0,Ardelyx shares are trading lower. This could be a potential profit taking from investors as the stock has been up approximately 177% over the past 30 days.,2019-09-13 07:44:00-04:00,ARDX,positive
90517.0,"The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans",2019-09-13 07:40:00-04:00,ARDX,neutral
90518.0,58 Biggest Movers From Yesterday,2019-09-13 07:04:00-04:00,ARDX,neutral
90519.0,Ardelyx Shares To Resume Trade At 3:40 p.m. EDT,2019-09-12 15:27:00-04:00,ARDX,positive
90520.0,"UPDATE: Ardelyx Pres, CEO Says 'I have great confidence that we are well positioned to file our NDA for hyperphosphatemia next year with potential approval and launch in 2021'",2019-09-12 15:15:00-04:00,ARDX,positive
90521.0,Ardelyx Issues Press Release Confirming FDA Approved IBSRELA For Treatment Of IBS With Constipation,2019-09-12 15:14:00-04:00,ARDX,positive
90522.0,Approval For Ardelyx's Ibsrela Has Boxed Warning For Risk Of Serious Dehydration In Pediatric Patients,2019-09-12 14:41:00-04:00,ARDX,negative
90523.0,"Ardelyx Shares Halted, News Pending",2019-09-12 14:39:00-04:00,ARDX,positive
90524.0,Ardelyx Shares Resume Trade,2019-09-12 14:37:00-04:00,ARDX,positive
90525.0,Ardelyx Granted FDA Approval For TENAPANOR,2019-09-12 14:34:00-04:00,ARDX,positive
90526.0,Ardelyx Shares Halted On Circuit Breaker,2019-09-12 14:33:00-04:00,ARDX,positive
90527.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-09-12 13:39:00-04:00,ARDX,neutral
90528.0,28 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-12 08:36:00-04:00,ARDX,neutral
90529.0,"The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study",2019-09-12 07:38:00-04:00,ARDX,negative
90530.0,"The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway",2019-09-11 07:09:00-04:00,ARDX,neutral
90531.0,84 Biggest Movers From Yesterday,2019-09-10 05:01:00-04:00,ARDX,neutral
90532.0,44 Stocks Moving In Monday's Mid-Day Session,2019-09-09 12:21:00-04:00,ARDX,neutral
90533.0,27 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-09-09 08:42:00-04:00,ARDX,neutral
90534.0,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",2019-09-08 11:01:00-04:00,ARDX,neutral
90535.0,60 Biggest Movers From Yesterday,2019-09-05 05:20:00-04:00,ARDX,neutral
90536.0,Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day,2019-09-04 16:42:00-04:00,ARDX,neutral
90537.0,46 Stocks Moving In Wednesday's Mid-Day Session,2019-09-04 12:27:00-04:00,ARDX,neutral
90538.0,"A Look At Benzinga Pro's Most-Searched Tickers For September 4, 2019",2019-09-04 12:07:00-04:00,ARDX,neutral
90539.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday., September 04, 2019",2019-09-04 09:21:00-04:00,ARDX,positive
90540.0,10 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-09-04 08:13:00-04:00,ARDX,neutral
90541.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,ARDX,positive
90542.0,66 Biggest Movers From Yesterday,2019-09-04 05:07:00-04:00,ARDX,neutral
90543.0,Why Are Shares Of Ardelyx Ripping Higher?,2019-09-03 14:43:00-04:00,ARDX,positive
90544.0,Mid-Afternoon Market Update: Dow Down 350 Points; MAM Software Shares Surge Following Acquisition News,2019-09-03 14:34:00-04:00,ARDX,positive
90545.0,44 Stocks Moving In Tuesday's Mid-Day Session,2019-09-03 12:34:00-04:00,ARDX,neutral
90546.0,Mid-Day Market Update: Napco Security Technologies Drops After Q4 Results; Cidara Therapeutics Shares Jump,2019-09-03 12:14:00-04:00,ARDX,positive
90547.0,Mid-Morning Market Update: Markets Open Lower; Conn's Beats Q2 Expectations,2019-09-03 10:22:00-04:00,ARDX,negative
90548.0,Ardelyx shares are trading higher after the company's pivotal phase 3 AMPLIFY study of tenapanor in combination with phosphate binders in patients with chronic kidney disease met primary and all key secondary endpoints.,2019-09-03 09:31:00-04:00,ARDX,positive
90549.0,32 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-03 08:42:00-04:00,ARDX,neutral
90550.0,Ardelyx Shares Resume Trade,2019-09-03 08:31:00-04:00,ARDX,positive
90551.0,Ardelyx Shares To Resume Trade At 8:30 a.m. EDT,2019-09-03 08:07:00-04:00,ARDX,positive
90552.0,Ardelyx Reports AMPLIFY Pivotal Phase  Study Of Tenapanor In Combination With Phosphate Binders In Patients With Chronic Kidney Disease Met Primary And All Key Secondary Endpoints,2019-09-03 08:02:00-04:00,ARDX,neutral
90553.0,"Ardelyx Shares Halted, News Pending",2019-09-03 07:56:00-04:00,ARDX,positive
90554.0,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates,2019-08-28 08:02:00-04:00,ARDX,neutral
90555.0,55 Biggest Movers From Yesterday,2019-08-21 05:07:00-04:00,ARDX,neutral
90556.0,44 Stocks Moving In Tuesday's Mid-Day Session,2019-08-20 12:21:00-04:00,ARDX,neutral
90557.0,72 Biggest Movers From Yesterday,2019-08-20 05:24:00-04:00,ARDX,neutral
90558.0,48 Stocks Moving In Monday's Mid-Day Session,2019-08-19 13:33:00-04:00,ARDX,neutral
90559.0,60 Biggest Movers From Friday,2019-08-19 05:00:00-04:00,ARDX,neutral
90560.0,Ardelyx Q1 EPS $(0.42) Misses $(0.39) Estimate,2019-05-07 17:38:00-04:00,ARDX,negative
90561.0,"Benzinga's Top Upgrades, Downgrades For April 8, 2019",2019-04-08 10:00:00-04:00,ARDX,positive
90562.0,PiperJaffray Initiates Coverage On Ardelyx with Overweight Rating,2019-04-08 07:04:00-04:00,ARDX,negative
90563.0,"The Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings",2019-03-08 07:38:00-05:00,ARDX,neutral
90564.0,64 Biggest Movers From Yesterday,2019-03-08 05:22:00-05:00,ARDX,neutral
90565.0,Ardelyx Highlights Peer-Reviewed Publication Of Positive Phase 3 Results Of Tenapanor For Treatment of Hyperphosphatemia In Journal Of The American Society Of Nephrology,2019-03-07 17:03:00-05:00,ARDX,positive
90566.0,"Ardelyx Q4 EPS $(0.45) Misses $(0.41) Estimate, Sales $85K Down From $42M YoY",2019-03-06 16:31:00-05:00,ARDX,negative
90567.0,"Ardelyx Reports Its Collaboration Partner, Kyowa Hakko Kirin, Initiated Phase 2 Study Of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan",2019-02-07 06:45:00-05:00,ARDX,neutral
90568.0,"Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan",2019-02-07 06:34:00-05:00,ARDX,neutral
90569.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,ARDX,negative
90570.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,ARDX,positive
90571.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,ARDX,negative
90572.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,ARDX,negative
90573.0,"The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch",2018-12-14 07:47:00-05:00,ARDX,neutral
90574.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,ARDX,negative
90575.0,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",2018-12-07 08:04:00-05:00,ARDX,neutral
90576.0,Ardelyx Reports FDA Acceptance Of Filing Of New Drug Application For Tenapanor In Treatment Of Patients With IBS-C,2018-11-13 08:31:00-05:00,ARDX,positive
90577.0,"Ardelyx Q3 EPS $(0.39) Beats $(0.41) Estimate, Sales $172K",2018-11-07 17:03:00-05:00,ARDX,neutral
90578.0,"Stocks Which Set New 52-Week Low Yesterday, October 31st",2018-11-01 10:37:00-04:00,ARDX,negative
90579.0,"Stocks Which Set New 52-Week Low Friday, October 26th",2018-10-29 09:56:00-04:00,ARDX,negative
90580.0,71 Biggest Movers From Friday,2018-10-29 05:33:00-04:00,ARDX,neutral
90581.0,"Ardelyx Reports New Preclinical Data Showing Synergy Between Tenapanor, Sevelamer When Dosed In Combo For Elevated Serum Phosphorus",2018-10-26 13:02:00-04:00,ARDX,neutral
90582.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,ARDX,negative
90583.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,ARDX,negative
90584.0,Ardelyx Showcases New Data From T3MPO-3 Long-Term Safety Trial Of Tenapanor For IBS-C In Presidential Poster At ACG 2018 Annual Meeting,2018-10-08 08:07:00-04:00,ARDX,positive
90585.0,Ardelyx Reports Submission Of New Drug Application For US Marketing Authorization Of Tenapanor For IBS-C,2018-09-13 06:32:00-04:00,ARDX,neutral
90586.0,"Benzinga's Top Upgrades, Downgrades For August 24, 2018",2018-08-24 09:13:00-04:00,ARDX,positive
90587.0,"Jefferies Initiates Coverage On Ardelyx with Buy Rating, Announces $7 Price Target",2018-08-24 06:38:00-04:00,ARDX,neutral
90588.0,Ardelyx Q2 EPS $(0.42) Beats $(0.44) Estimate,2018-08-07 16:15:00-04:00,ARDX,neutral
90589.0,45 Biggest Movers From Tuesday,2018-07-05 04:40:00-04:00,ARDX,neutral
90590.0,"Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings",2018-05-24 08:37:00-04:00,ARDX,neutral
90591.0,38 Biggest Movers From Yesterday,2018-05-24 04:44:00-04:00,ARDX,neutral
90592.0,Mid-Afternoon Market Update: Tiffany Rises Following Q1 Beat; Red Robin Shares Plummet,2018-05-23 14:32:00-04:00,ARDX,positive
90593.0,33 Stocks Moving In Wednesday's Mid-Day Session,2018-05-23 12:53:00-04:00,ARDX,neutral
90594.0,Mid-Day Market Update: Dow Falls Over 100 Points; Cara Therapeutics Shares Spike Higher,2018-05-23 12:16:00-04:00,ARDX,positive
90595.0,Mid-Morning Market Update: Markets Open Lower; Target Earnings Miss Views,2018-05-23 10:45:00-04:00,ARDX,negative
90596.0,Ardelyx Late Tuesday Priced 12.5M Share Offering At $4.00/Share; Shares Down 13.2%,2018-05-23 09:35:00-04:00,ARDX,positive
90597.0,20 Stocks Moving In Wednesday's Pre-Market Session,2018-05-23 08:36:00-04:00,ARDX,neutral
90598.0,"Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing",2018-05-23 08:15:00-04:00,ARDX,neutral
90599.0,38 Biggest Movers From Yesterday,2018-05-23 04:56:00-04:00,ARDX,neutral
90600.0,Mid-Afternoon Market Update: Dow Down 75 Points; Ardelyx Shares Slide,2018-05-22 14:23:00-04:00,ARDX,positive
90601.0,32 Stocks Moving In Tuesday's Mid-Day Session,2018-05-22 12:24:00-04:00,ARDX,neutral
90602.0,Mid-Day Market Update: Dycom Industries Falls On Q3 Miss; America's Car-Mart Shares Gain,2018-05-22 12:00:00-04:00,ARDX,positive
90603.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-05-22 08:05:00-04:00,ARDX,neutral
90604.0,"Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict",2018-05-22 08:05:00-04:00,ARDX,positive
90605.0,8 Stocks Moving In Monday's After-Hours Session,2018-05-21 17:34:00-04:00,ARDX,neutral
90606.0,Ardelyx Shares Down 10.6% After Hours Following Announcement Of $50M Common Stock Offering,2018-05-21 17:34:00-04:00,ARDX,positive
90607.0,"Ardelyx Reports Entered Into $50M Senior Secured Term Loan Facility With Solar Capital, Life Sciences Group At Bridge Bank",2018-05-21 16:03:00-04:00,ARDX,positive
90609.0,"Ardelyx Q1 EPS $(0.36) Beats $(0.46) Estimate, Made $1.85M Sales",2018-05-08 16:54:00-04:00,ARDX,neutral
90610.0,36 Biggest Movers From Yesterday,2018-04-19 04:28:00-04:00,ARDX,neutral
90611.0,"Ardelyx Reports Q4 EPS $0.21 Does Not Compare To $(0.41) Est., Sales $33.6M",2018-03-14 16:30:00-04:00,ARDX,neutral
90612.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-01-03 08:08:00-05:00,ARDX,neutral
90613.0,Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C,2018-01-03 06:31:00-05:00,ARDX,positive
90614.0,"Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China, Co. To Receive Up To $125M In Upfront Payment And Subsequent Milestones",2017-12-11 06:01:00-05:00,ARDX,positive
90615.0,40 Biggest Movers From Yesterday,2017-11-29 05:02:00-05:00,ARDX,neutral
90616.0,35 Stocks Moving In Tuesday's Mid-Day Session,2017-11-28 12:23:00-05:00,ARDX,neutral
90617.0,30 Stocks Moving In Tuesday's Pre-Market Session,2017-11-28 08:08:00-05:00,ARDX,neutral
90618.0,"Ardelyx, Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan; Ardelyx to Receive $30M Upfront Payment Plus Milestones",2017-11-28 04:33:00-05:00,ARDX,positive
90619.0,40 Biggest Movers From Yesterday,2017-11-22 05:03:00-05:00,ARDX,neutral
90620.0,40 Stocks Moving In Tuesday's Mid-Day Session,2017-11-21 12:42:00-05:00,ARDX,neutral
90621.0,33 Stocks Moving In Tuesday's Pre-Market Session,2017-11-21 08:08:00-05:00,ARDX,neutral
90622.0,"Ardelyx Give and Updated Development Path for its Cardiorenal Pipeline, Discontinues RDX7675, Second Registration Study for Tenapanor to Begin",2017-11-21 06:36:00-05:00,ARDX,neutral
90623.0,"Ardelyx Q3 EPS $(0.44) vs $(0.54) Est., No Sales",2017-11-07 06:40:00-05:00,ARDX,negative
90624.0,Ardelyx 13G Filing From Rock Springs Capital Shows 5.02% Stake,2017-11-02 10:20:00-04:00,ARDX,neutral
90625.0,32 Biggest Movers From Yesterday,2017-10-18 03:53:00-04:00,ARDX,neutral
90626.0,35 Biggest Movers From Yesterday,2017-10-17 04:52:00-04:00,ARDX,neutral
90627.0,Ardelyx Down ~8% As Co. Earlier Announced Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling; Mentioned In PR That They Will Move Forward To Submit NDA To FDA In Second Half Of 2018,2017-10-16 12:33:00-04:00,ARDX,negative
90628.0,Mid-Afternoon Market Update: Crude Oil Down 2%; Infinity Pharmaceuticals Shares Spike Higher,2017-10-12 14:30:00-04:00,ARDX,negative
90629.0,33 Stocks Moving In Thursday's Mid-Day Session,2017-10-12 12:40:00-04:00,ARDX,neutral
90630.0,Mid-Day Market Update: J.Jill Tumbles Following Weak Q3 Outlook; Ardelyx Shares Surge,2017-10-12 12:22:00-04:00,ARDX,negative
90631.0,Ardelyx Up 50% After Positive Phase 3 Study Of Tenapanor,2017-10-12 12:15:00-04:00,ARDX,positive
90632.0,Mid-Morning Market Update: Markets Edge Lower; JPMorgan Profit Beats Estimates,2017-10-12 10:14:00-04:00,ARDX,positive
90633.0,30 Stocks Moving In Thursday's Pre-Market Session,2017-10-12 08:03:00-04:00,ARDX,neutral
90634.0,"Ardelyx Shares Resume Trade, Now Indicated Up 39%",2017-10-11 16:31:00-04:00,ARDX,positive
90635.0,Ardelyx Shares To Resume Trade At 4:30 p.m. EDT,2017-10-11 16:08:00-04:00,ARDX,positive
90636.0,"Ardelx Pivotal Phase 3 Study Of Tenapanor Hits Primary And All Secondary Endpoints, Supporting NDA Submission in 2018",2017-10-11 16:04:00-04:00,ARDX,positive
90637.0,"Ardelyx Shares Halted, News Pending",2017-10-11 16:03:00-04:00,ARDX,positive
90638.0,"Shares Of Gastrointestinal Drug Companies Ardelyx and Synergy Pharma Each Higher On Heavy Volume; ARDX Up 11.61% At $6.25, SGYP Up 11.9% At $3.24",2017-10-02 14:32:00-04:00,ARDX,positive
90639.0,13G Filing Shows Deerfield Mgmt Reporting 5.79% Stake In Ardelyx,2017-08-31 14:23:00-04:00,ARDX,neutral
90640.0,"Ardelyx Q2 EPS $(0.54) vs $(0.64) Est., Cuts Workforce by 28%, Expecting Data in Q4",2017-08-09 06:38:00-04:00,ARDX,negative
90641.0,"Companies Holding Shareholder Meetings Today Include: Athenahealth, Ambarella, Arcadia Biosciences, Ardelyx, Alphabet, Credit Acceptance, Express, Dick's Sporting Goods, Check Point Software, Hubspot, GoDaddy, Shutterstock, Shopify, And Vitamin Shoppe",2017-06-07 09:03:00-04:00,ARDX,positive
90642.0,Mid-Afternoon Market Update: Inpixon Drops Following Q1 Results; Technical Communications Shares Spike Higher,2017-05-12 14:30:00-04:00,ARDX,positive
90643.0,18 Biggest Mid-Day Losers For Friday,2017-05-12 12:52:00-04:00,ARDX,negative
90644.0,Mid-Day Market Update: Trade Desk Rises After Q1 Results; Capricor Therapeutics Shares Slide,2017-05-12 12:04:00-04:00,ARDX,positive
90645.0,Mid-Morning Market Update: Markets Open Lower; J C Penney Reports Weak Sales,2017-05-12 10:16:00-04:00,ARDX,negative
90646.0,Ardelyx Reports Phase 3 T3MPO-1 Trial of Tenapanor in Patients With IBS-C  Achieves Primary Endpoint,2017-05-12 06:31:00-04:00,ARDX,neutral
90647.0,Ardelyx Reports Q1 EPS $(0.59) vs $(0.68) Est.,2017-05-05 06:40:00-04:00,ARDX,neutral
90648.0,S-3 from Ardelyx Shows Registration for $250M Mixed Securities Shelf Offering,2017-04-24 17:34:00-04:00,ARDX,positive
90649.0,UPDATE: Ardelyx Says Sees Data from Onset-of-Action Trial of RDX7675 for Hyperkalemia in Q3'17,2017-03-21 17:13:00-04:00,ARDX,neutral
90650.0,UPDATE: Ardelyx Says Sees Pivotal Phase 3 Trial Evaluating Tenapanor in IBS-C Patients (T3MPO-1) During Q2'17,2017-03-21 17:12:00-04:00,ARDX,neutral
90651.0,"UPDATE: Ardelyx Says Co. Achieved Full Enrollment of 300+ Patients for Open-Label, Long-Term Safety Study in Which Patients Received Tenapanor for Up to 1 Year",2017-03-21 17:11:00-04:00,ARDX,positive
90652.0,"UPDATE: Ardelyx Says Achieved Full Enrollment of 600+ Patients for Pivotal Phase 3 Trial Evaluating Tenapanor in IBS-C Patients, Sees Results During 2H'17",2017-03-21 17:11:00-04:00,ARDX,neutral
90653.0,"8-K from Ardelyx Shows Co. Offered 4 Updates to Progress, Projections Related to Certain Programs, Ongoing Trials",2017-03-21 17:10:00-04:00,ARDX,positive
90654.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,ARDX,neutral
90655.0,"Cowen Annual Healthcare Conference Begins Today; Presenters Include Insulet, PARAXEL, Zoetis, Alexion, Bristol-Myers, Acadia, Alnylam, Axovant, Ardelyx, Aurinia Pharma, And Puma Biotech",2017-03-06 08:39:00-05:00,ARDX,neutral
90656.0,BZ NOTE: Wedbush Mentioned Ardelyx As A Takeover Candidate Yesterday In A Mid-Day Note,2017-02-23 14:32:00-05:00,ARDX,positive
90657.0,"Ardelyx Shares Spiking Higher, Hearing Vague Takeover Chatter",2017-02-23 14:30:00-05:00,ARDX,positive
90658.0,Wedbush Has A New Best Idea For 2017: Ardelyx,2017-02-23 07:09:00-05:00,ARDX,positive
90659.0,"Ardelyx Shares Spiking On Wedbush Calling Co. Best Idea For 2017, Says It's Likely Takeout Candidate",2017-02-22 13:38:00-05:00,ARDX,positive
90660.0,"Ardelyx Reports Q4 EPS $(0.66), Inline",2017-02-17 16:07:00-05:00,ARDX,neutral
90661.0,Ardelyx Says Phase 3 Efficacy and Safety Trial Met Primary Endpoint,2017-02-15 06:33:00-05:00,ARDX,positive
90662.0,Ardelyx Initiates of Two Clinical Trials of RDX7675 for Treatment of Hyperkalemia,2017-01-03 06:35:00-05:00,ARDX,neutral
90663.0,Ardelyx Reports Q3 EPS $(0.65) vs $(0.74) Est.,2016-11-07 16:05:00-05:00,ARDX,neutral
90664.0,Ardelyx Names Reinald Seeto COO,2016-10-24 07:01:00-04:00,ARDX,neutral
90665.0,Ardelyx Announces Positive IBS-C Phase 2 Endpoint Data,2016-10-19 07:05:00-04:00,ARDX,positive
90666.0,Ardelyx Reports Q2 EPS $(0.83) vs. Est. $(0.75),2016-08-08 16:37:00-04:00,ARDX,neutral
90667.0,Ardelyx Receives Notice of Allowance of Composition of Matter Patent Covering its Novel Potassium Binder RDX227675,2016-08-01 08:04:00-04:00,ARDX,positive
90668.0,Ardelyx to Raise $110M in Private Placement,2016-07-15 08:01:00-04:00,ARDX,neutral
90669.0,"Ardelyx Reports Positive Results From EoP2 Trial, Also Reports Positive Pharmacodynamic Trial Results Fro RDX227675 For Hyperkalemia",2016-06-22 07:03:00-04:00,ARDX,positive
90670.0,Ardelyx Names Robert Bazemore to Board,2016-06-07 06:20:00-04:00,ARDX,neutral
90671.0,Ardelyx Reports Q1 EPS $(0.70) Vs Est $(0.66),2016-05-09 16:02:00-04:00,ARDX,neutral
90672.0,Benzinga's Top Initiations,2016-03-31 09:11:00-04:00,ARDX,positive
90673.0,"Ladenburg Thalmann Initiates Coverage on Ardelyx at Buy, Announces $21.00 PT",2016-03-31 07:02:00-04:00,ARDX,neutral
90674.0,More Mid-Cap Biotech M&A May Be Coming,2016-03-29 11:32:00-04:00,ARDX,neutral
90675.0,"Cantor Fitzgerald Initiates Coverage on Ardelyx at Buy, Announces $19.00 PT",2016-03-08 16:22:00-05:00,ARDX,neutral
90676.0,Ardelyx Reports Q4 EPS $(0.65) Vs Est $(0.81),2016-03-04 06:03:00-05:00,ARDX,neutral
90677.0,Benzinga's Top Initiations,2016-03-03 10:01:00-05:00,ARDX,positive
90678.0,"Citigroup Initiates Coverage on Ardelyx at Buy, Announces $15.00 PT",2016-03-03 07:21:00-05:00,ARDX,neutral
90679.0,Here Are The Most Notable Insider Transactions Hitting The Market,2016-01-26 13:19:00-05:00,ARDX,neutral
90680.0,"Chairman Mott Buys 1,000,000 Shares of Ardelyx @$10.00/Share -Form 4",2016-01-14 16:33:00-05:00,ARDX,positive
90681.0,Benzinga's Volume Movers,2016-01-08 10:26:00-05:00,ARDX,neutral
90682.0,Benzinga's Top #PreMarket Gainers,2016-01-08 08:12:00-05:00,ARDX,positive
90683.0,Ardelyx Prices 7.5M Share Offering @$10.00/Share,2016-01-07 20:48:00-05:00,ARDX,positive
90684.0,Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Uniqure Shares Gain Following Release Of Clinical Trial Data,2016-01-07 15:02:00-05:00,ARDX,positive
90685.0,Mid-Day Market Update: Finish Line Drops On Weak Results; Dynavax Shares Spike Higher,2016-01-07 12:03:00-05:00,ARDX,negative
90686.0,Here's Why There's Been A Rush Of Biotech Offerings,2016-01-07 11:32:00-05:00,ARDX,neutral
90687.0,Mid-Morning Market Update: Markets Open Lower; KB Home Misses Q4 Views,2016-01-07 09:54:00-05:00,ARDX,negative
90688.0,Ardelyx Reports Offering of $75M in Common Shares,2016-01-06 16:34:00-05:00,ARDX,positive
90689.0,Ardelyx Announces Positive Results of RDX022 Study,2016-01-05 06:02:00-05:00,ARDX,positive
90690.0,Ardelyx Names Dr. Paul Korner Chief Medical Officer,2016-01-04 08:02:00-05:00,ARDX,neutral
90691.0,Ardelyz Reports Q3 EPS $(0.70) Vs Est $(0.48),2015-11-12 07:01:00-05:00,ARDX,neutral
90692.0,Morning Market Gainers,2015-10-26 11:32:00-04:00,ARDX,neutral
90693.0,Ardelyx to Present Phase 2 Data for Tenapanor in IBS-C Patients at the 2015 American College of Gastroenterology Annual Meeting,2015-10-08 16:30:00-04:00,ARDX,neutral
90694.0,"Ardelyx Reports Q2 EPS $0.43, Sales $18.143M vs $25.9M Est.",2015-08-12 06:04:00-04:00,ARDX,neutral
90695.0,Ardelyx Says Plans to File IND in the Second Half of 2016,2015-07-14 06:04:00-04:00,ARDX,neutral
90696.0,S-3 Filing For Ardelyx Shows Offering Of 9.416M Shares By Selling Shareholders,2015-07-13 09:20:00-04:00,ARDX,positive
90697.0,Form D from Ardelyx Shows Total Offering Size of Nearly $108M,2015-06-22 14:15:00-04:00,ARDX,neutral
90698.0,Benzinga's Volume Movers,2015-06-15 10:27:00-04:00,ARDX,neutral
90699.0,Morning Market Gainers,2015-06-03 09:41:00-04:00,ARDX,neutral
90700.0,"US Stock Futures Surge Ahead Of ADP Report, Beige Book",2015-06-03 07:30:00-04:00,ARDX,neutral
90701.0,"Ardelyx Regains Worldwide Development, Commercialization Rights for Tenapanor and Related Portfolio of NHE3 Compounds",2015-06-03 06:23:00-04:00,ARDX,neutral
90702.0,Ardelyx to Raise $77.8M in Private Placement; Announces New Product Candidate for Treatment of Hyperkalemia to Begin Clinical Development in Mid-2015,2015-06-03 06:21:00-04:00,ARDX,neutral
90703.0,Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients at Digestive Disease Week 2015,2015-05-19 14:58:00-04:00,ARDX,positive
90704.0,"Ardelyx Reports Q1 EPS $(0.19) vs. Est. $0.01, Rev. $5.883M vs. Est. $10.95M; Estimates May Not Compare",2015-05-12 16:18:00-04:00,ARDX,neutral
90705.0,"Ardelyx Reports Q1 Loss $0.19 Vs Est Gain $0.01, May Not Compare, Sales $5.88M",2015-05-12 16:16:00-04:00,ARDX,positive
90706.0,Morning Market Losers,2015-05-06 09:56:00-04:00,ARDX,negative
90707.0,Ardelyx Shares Resume Trading Now Down 26%,2015-05-05 16:39:00-04:00,ARDX,positive
90708.0,Shares of Ardelyx to Resume Trade at 4:35 p.m. EDT,2015-05-05 16:12:00-04:00,ARDX,positive
90709.0,Ardelyx Reports Results from Phase 2a Clincial Trial Evaluating Tenapanor in Chronic Kidney Disease Patients,2015-05-05 16:07:00-04:00,ARDX,neutral
90710.0,Ardelyx Shares Halted News Pending,2015-05-05 16:01:00-04:00,ARDX,positive
90711.0,Ardelyx Reports Fourth Quarter EPS of $(0.21),2015-02-25 16:27:00-05:00,ARDX,neutral
90712.0,Morning Market Losers,2015-02-02 09:56:00-05:00,ARDX,negative
90713.0,Ardelyx Says Astrazeneca's Phase 2b Clinical Trial Evaluating Tenapanor Met Primary Endpoint,2015-02-02 07:22:00-05:00,ARDX,neutral
90714.0,From 13D: New Enterprise Associates Reports 30.4% Stake In Ardelyx,2014-12-18 16:43:00-05:00,ARDX,neutral
90715.0,"Ardelyx Announces Tenapanor Reduces Phosphorus Absorption, Protects Against Vascular Calcification in Preclinical In Vivo Model of Kidney Disease, Expecting Ongoing Phase 2b Trial in Q1 of 2015",2014-11-17 17:07:00-05:00,ARDX,positive
90716.0,"Midday Gainers From October 1 - Angie's List Inc, Tekmira Pharmaceuticals Corporation And More",2014-10-01 12:52:00-04:00,ARDX,neutral
90717.0,Morning Market Movers ,2014-10-01 09:39:00-04:00,ARDX,neutral
90718.0,Ardelyx Announces Positive Results from Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients; Primary Endpoint Met ,2014-10-01 06:01:00-04:00,ARDX,positive
90719.0,Ardelyx Reports Q2 EPS of $0.18 Which May Not Compare $0.00 Est; Revenue of $9.10M Which May Not Compare $9.23M Est,2014-08-07 09:02:00-04:00,ARDX,neutral
90720.0,"Leerink Swann Initiates Coverage on Ardelyx at Outperform, Announces $32.00 PT",2014-07-14 09:10:00-04:00,ARDX,neutral
90721.0,"Citigroup Initiates Coverage on Ardelyx at Buy, Announces $27.00 PT",2014-07-14 09:10:00-04:00,ARDX,neutral
90722.0,Benzinga's Top Initiations,2014-07-14 08:51:00-04:00,ARDX,positive
90723.0,JMP Securities Initiates Ardelyx With Market Outperform,2014-07-14 08:20:00-04:00,ARDX,positive
90724.0,UPDATE: JMP Securities Initiates Coverage On Ardelyx Following Valuation Analyses,2014-07-14 08:06:00-04:00,ARDX,positive
90725.0,"JMP Securities Initiates Coverage on Ardelyx at Market Outperform, Announces $26.00 PT",2014-07-14 06:44:00-04:00,ARDX,positive
90726.0,13D Filing from New Enterprise Asset Mgmt on Ardelyx Shows 35.7% Stake,2014-07-01 15:38:00-04:00,ARDX,positive
90727.0,"Ardelyx Reports Closing of Offering, Announces Underwritters Fully Exercised Option to Buy Added Shares, Co. Expecting Net Proceeds ~$60.8M",2014-06-24 16:33:00-04:00,ARDX,positive
90728.0,"Shares of Ardelyx Open for Trade at $14.5/Share, Priced at $14",2014-06-19 10:51:00-04:00,ARDX,positive
90729.0,Waiting on 5 IPOs This Morning,2014-06-19 08:35:00-04:00,ARDX,neutral
90730.0,IPO Lookout: 14 IPOs For The Week Of June 16,2014-06-16 09:25:00-04:00,ARDX,neutral
90731.0,"Ardelyx Files $69M IPO, Will List on NASDAQ Under 'ARDX'",2014-05-19 17:17:00-04:00,ARDX,neutral
